FDA accepts Shire's Fosrenol NDA

Shire Pharmaceuticals (LSE:SHP; SHPGY) said the FDA accepted for filing its NDA for Fosrenol lanthanum carbonate formulation to treat chronic renal failure. SHP has an exclusive license to the compoun...